EG 427 is pioneering the use of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a novel gene therapy platform aimed at treating chronic diseases, particularly those affecting the peripheral nervous system. This innovative approach leverages the natural properties of HSV-1 to establish lifelong latency in peripheral neurons, allowing for the safe and durable expression of therapeutic genes. The company focuses on developing vectors that can carry large genetic payloads, exceeding 30 kilobases, which enables the inclusion of complex regulatory elements to finely tune gene expression. This technology is designed to provide targeted and long-lasting effects, particularly in treating conditions like neurogenic detrusor overactivity and overactive bladder, which have significant unmet medical needs.

In addition to its advanced vector technology, EG 427 has established a robust manufacturing infrastructure to support the production of its gene therapy products. The company employs specialized producer cell lines to enhance manufacturing efficiency and quality, ensuring that their processes meet GMP-grade standards. This capability allows EG 427 to deliver large volumes of its gene therapies at a lower cost, addressing the challenges associated with treating major chronic diseases. By continuously engineering its vector platform, EG 427 aims to expand its therapeutic applications beyond the peripheral nervous system, exploring various localized chronic conditions and enhancing the overall efficacy of its gene therapy solutions.

France

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. 

Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.

EG 427

Company Details